By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nerviano Medical Sciences (NervianoMS) 

Viale Pasteur, 10

Milano    20014  Italy
Phone: 39-0331-58-1111 Fax: n/a


NMS Group is the largest Italian company committed in innovation and research and development in oncology. With 450 total employees, NMS Group employs over 200 qualified researchers involved in research and development, from 'target validation' to phase II clinical trials.

The discovery and applied research of Nerviano Medical Sciences

- representing the innovative heart of the Group and make it an important and international reference in the field of personalized therapy

- integrate with other development activities of a new drug.

NMS Group is, in fact, the only reality in Italy able to manage the entire integrated chain of the research and development path: from pre-clinical phase of research, to First-Time-In-Man of clinical phase, up to production and packaging of the finished drug.

NMS also provides services of Research and Production addressed to local and international markets through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and Nerpharma, dealing with activities from formulation to production of the active principle.

Key Statistics

Ownership: Private

Web Site: Nerviano Medical Sciences

Company News
TrovaGene (TROV) And Nerviano Medical Sciences Announce License Agreement For Therapeutic Candidate PCM-075 3/16/2017 6:39:57 AM
Nerviano Medical Sciences (NervianoMS) Presents Data Regarding A Potent New Cytotoxic Molecule For ADC Generation 10/20/2016 11:17:06 AM
Oxford BioTherapeutics Licenses Nerviano Medical Sciences (NervianoMS)' Drug-Linker Technology To Develop Novel Antibody Drug Conjugates 4/4/2016 6:28:40 AM
Tiziana Life Sciences Plc Licenses Milciclib From Nerviano Medical Sciences (NervianoMS) 1/20/2015 9:32:11 AM
Ignyta (RXDX) Announces Amendment To License Agreement With Nerviano Medical Sciences (NervianoMS) 12/15/2014 10:14:02 AM
Ignyta (RXDX) And Nerviano Medical Sciences (NervianoMS) Announce License Agreement For Two First-in-Class Kinase Inhibitors 8/5/2014 10:28:01 AM
Cellectis And Accelera (Nerviano Medical Sciences (NervianoMS)) Sign An Agreement To Complete Preclinical Studies Of Cellectis’ Lead Product Candidate UCART19 6/5/2014 12:47:32 PM
Nerviano Medical Sciences (NervianoMS) and Servier Announce a Collaboration and License Agreement for a Novel Anticancer Drug 7/30/2013 9:26:41 AM
Professor Carlo Maria Croce Joins the Board of Nerviano Medical Sciences (NervianoMS) 10/26/2011 10:59:06 AM
Nerviano Medical Sciences (NervianoMS) Announces New License Agreement 3/15/2011 8:56:23 AM